October 14th, 2026The One Thing: What ophthalmologists aren’t talking about enough | Episode 1Timothy M. Janetos, MD, Donald J. D’Amico, MD, and Mark J. Gallardo, MD, point to uveitis access, clinical trial rigor, and procedural pharmaceuticals.Read more
October 14th, 2026AAO 2026: How subcutaneous elegrobart could change TED careAt AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye disease.Read more
October 11th, 2026AAO 2026: Inside an ophthalmic medical mission to ArmeniaJohn A. Hovanesian, MD, discusses the Armenian Eyecare Project’s annual trip, from preparation and surgery to teaching and student involvement.Read more
October 11th, 2026AAO 2026: Elegrobart reduces proptosis in active thyroid eye diseaseAt AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED.Read more
October 11th, 2026AAO 2026: New trials target optic neuritis treatment questionsJohn J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.Read more
October 11th, 2026AAO 2026: Are topical antibiotics necessary after intracameral prophylaxis in cataract surgery: is enough enough?A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis. Read more
October 10th, 2026AAO 2026: BRUNELLO 1-year results for remigromig in DMEDonald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular edema. Read more
October 10th, 2026AAO 2026: 24-month outcomes of excimer laser trabeculostomyMark J. Gallardo, MD, discusses how the laser performed alongside cataract surgery in open-angle glaucoma, including medication burden and safety.Read more